Skip to main content
Erschienen in: Journal of Gastroenterology 6/2011

01.06.2011 | Original Article—Liver, Pancreas, and Biliary Tract

Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids

verfasst von: Kensuke Kubota, Seitaro Watanabe, Takashi Uchiyama, Shingo Kato, Yusuke Sekino, Kaori Suzuki, Hironori Mawatari, Hiroshi Iida, Hiroki Endo, Koji Fujita, Masato Yoneda, Hirokazu Takahashi, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Satoru Saito, Kazuya Sugimori, Kantaro Hisatomi, Nobuyuki Matsuhashi, Hirotaka Sato, Emiko Tanida, Takashi Sakaguchi, Nobutaka Fujisawa, Atsushi Nakajima

Erschienen in: Journal of Gastroenterology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Relapse and spontaneous remission (SR) are characteristic features of autoimmune pancreatitis (AIP).

Aim and methods

We conducted a study to determine if the predictive factors might be potentially related to the relapse in 70 consecutive AIP patients. Regarding SR, we studied the data of patients without corticosteroid treatment (CST).

Results

CST was administered to 60% (42/70) of the patients; however, relapse was noted in 45.2% (19/42) of these patients. In 95% (18/19) of the AIP patients developing relapse, the relapse occurred within 3 years. The relapse rate was 80% (12/15) in the AIP patients administered CST for less than 12 months and 25.9% (7/27) in those administered CST for over 12 months (p < 0.01). The results of univariate analysis revealed significant association of relapse with the presence of jaundice, IgG4 seropositivity, presence of diffuse pancreas swelling, duodenal papillitis (DP), history of initial CST, and history of supportive treatment (p < 0.05), whereas multivariate analysis revealed that IgG4 seropositivity (OR 10.506, p = 0.0422) and the presence of jaundice (OR 6.945, p = 0.0174) are significant independent factors predictive of relapse in AIP patients. SR was recognized in 65.0% (13/20) of AIP patients without CST. The results of univariate analysis revealed that SR was associated with IgG4 seropositivity (p < 0.05), and multivariate analysis identified IgG4 seropositivity (OR 0.032, p = 0.0092) as a significant independent factor predictive of SR in these cases.

Conclusion

AIP patients with IgG4 seropositivity and jaundice are at a higher risk of relapse and they could therefore be candidates for over 3 years of maintenance CST. AIP patients with IgG4 seronegativity have a high likelihood of SR.
Literatur
1.
Zurück zum Zitat Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas: an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688–98.PubMedCrossRef Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas: an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688–98.PubMedCrossRef
2.
Zurück zum Zitat Yoshida K, Toki F, Takeuti T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.PubMedCrossRef Yoshida K, Toki F, Takeuti T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.PubMedCrossRef
3.
Zurück zum Zitat Hamano H, Kawa S, Horiuchi A, Unnno H, Furuta N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.PubMedCrossRef Hamano H, Kawa S, Horiuchi A, Unnno H, Furuta N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.PubMedCrossRef
4.
Zurück zum Zitat Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet. 1999;354:43–4.PubMedCrossRef Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet. 1999;354:43–4.PubMedCrossRef
5.
Zurück zum Zitat Kubota K, Iida H, Fujisawa T, Yoneda M, Inamori M, Kirikoshi H, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66:1142–51.PubMedCrossRef Kubota K, Iida H, Fujisawa T, Yoneda M, Inamori M, Kirikoshi H, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66:1142–51.PubMedCrossRef
6.
Zurück zum Zitat Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N. Long-term prognosis of duct-narrowing chronic pancreatitis. Strategy for steroid treatment. Pancreas. 2005;30:31–9.PubMed Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N. Long-term prognosis of duct-narrowing chronic pancreatitis. Strategy for steroid treatment. Pancreas. 2005;30:31–9.PubMed
7.
Zurück zum Zitat Takayama M, Hamano H, Ochi Y, et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol. 2004;99:932–7.PubMedCrossRef Takayama M, Hamano H, Ochi Y, et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol. 2004;99:932–7.PubMedCrossRef
8.
Zurück zum Zitat Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2006;56:1719–24.CrossRef Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2006;56:1719–24.CrossRef
9.
Zurück zum Zitat Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139:140–8.PubMedCrossRef Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139:140–8.PubMedCrossRef
10.
Zurück zum Zitat Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levt MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.PubMedCrossRef Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levt MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.PubMedCrossRef
11.
Zurück zum Zitat Kubota K, Iida H, Fujisawa T, Ogawa M, Inamori M, Saito S, Kakuta Y, Oshiro H, Nakajima A. Clinical significance of swollen duodenal papilla in autoimmune pancreatitis. Pancreas. 2007;35:e51–60.PubMedCrossRef Kubota K, Iida H, Fujisawa T, Ogawa M, Inamori M, Saito S, Kakuta Y, Oshiro H, Nakajima A. Clinical significance of swollen duodenal papilla in autoimmune pancreatitis. Pancreas. 2007;35:e51–60.PubMedCrossRef
12.
Zurück zum Zitat Otsuki M, Chung JB, Okazaki K, Kim MH, Kamisawa T, Kawa S, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan–Korea symposium on autoimmune pancreatitis. J Gastroenterol. 2008;43:403–8.PubMedCrossRef Otsuki M, Chung JB, Okazaki K, Kim MH, Kamisawa T, Kawa S, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan–Korea symposium on autoimmune pancreatitis. J Gastroenterol. 2008;43:403–8.PubMedCrossRef
13.
Zurück zum Zitat Bodily KD, Takahashi N, Fletcher JG, Finder J, Hough DM, Kawashima A, Chari ST. Autoimmune pancreatitis: pancreatic and extrapancreatic imaging findings. AJR. 2009;192:431–7.PubMedCrossRef Bodily KD, Takahashi N, Fletcher JG, Finder J, Hough DM, Kawashima A, Chari ST. Autoimmune pancreatitis: pancreatic and extrapancreatic imaging findings. AJR. 2009;192:431–7.PubMedCrossRef
14.
Zurück zum Zitat Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid therapy for autoimmune pancreatitis. GUT. 2009;58:1504–7.PubMedCrossRef Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid therapy for autoimmune pancreatitis. GUT. 2009;58:1504–7.PubMedCrossRef
15.
Zurück zum Zitat Ghazale A, Chari S. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007;56:1650–2.PubMedCrossRef Ghazale A, Chari S. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007;56:1650–2.PubMedCrossRef
16.
17.
Zurück zum Zitat Nakazawa T, Ohara H, Sano H, Ando T, Joh T. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas. 2006;32:229.PubMedCrossRef Nakazawa T, Ohara H, Sano H, Ando T, Joh T. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas. 2006;32:229.PubMedCrossRef
18.
Zurück zum Zitat Ito T, Nishimori I, Inoue N, Kawabe K, Gibo J, Arita Y, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;24(Suppl 18):50–8.CrossRef Ito T, Nishimori I, Inoue N, Kawabe K, Gibo J, Arita Y, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;24(Suppl 18):50–8.CrossRef
19.
Zurück zum Zitat Unno H, Saegusa H, Fukushima M, Hamano H. Usefulness of endoscopic observation of the main duodenal papilla in the diagnosis of sclerosing pancreatitis. Gastrointest Endosc. 2002;56:880–4.PubMedCrossRef Unno H, Saegusa H, Fukushima M, Hamano H. Usefulness of endoscopic observation of the main duodenal papilla in the diagnosis of sclerosing pancreatitis. Gastrointest Endosc. 2002;56:880–4.PubMedCrossRef
20.
Zurück zum Zitat Nishimori I, Tamakoshi A, Kawa S, Tanaka S, Takeuti K, Kamisawa T, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006;32:244–8.PubMedCrossRef Nishimori I, Tamakoshi A, Kawa S, Tanaka S, Takeuti K, Kamisawa T, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006;32:244–8.PubMedCrossRef
21.
Zurück zum Zitat Ito T, Kawabe K, Arita Y, Hisano T, Igarashi H, Funakoshi A, et al. Evaluation of pancreatic endocrine function in patients with autoimmune pancreatitis. Pancreas. 2006;34:254–9.CrossRef Ito T, Kawabe K, Arita Y, Hisano T, Igarashi H, Funakoshi A, et al. Evaluation of pancreatic endocrine function in patients with autoimmune pancreatitis. Pancreas. 2006;34:254–9.CrossRef
22.
Zurück zum Zitat Uchida K, Yazumi S, Nishio A, Kusuda T, Koyabu M, Furuta M, et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.PubMedCrossRef Uchida K, Yazumi S, Nishio A, Kusuda T, Koyabu M, Furuta M, et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.PubMedCrossRef
23.
Zurück zum Zitat Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.CrossRef Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2009;44:726–32.CrossRef
24.
Zurück zum Zitat Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M, working members of research committee for intractable pancreatic disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45:471–7.PubMedCrossRef Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M, working members of research committee for intractable pancreatic disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45:471–7.PubMedCrossRef
25.
Zurück zum Zitat Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134:440–6.CrossRef Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134:440–6.CrossRef
Metadaten
Titel
Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids
verfasst von
Kensuke Kubota
Seitaro Watanabe
Takashi Uchiyama
Shingo Kato
Yusuke Sekino
Kaori Suzuki
Hironori Mawatari
Hiroshi Iida
Hiroki Endo
Koji Fujita
Masato Yoneda
Hirokazu Takahashi
Hiroyuki Kirikoshi
Noritoshi Kobayashi
Satoru Saito
Kazuya Sugimori
Kantaro Hisatomi
Nobuyuki Matsuhashi
Hirotaka Sato
Emiko Tanida
Takashi Sakaguchi
Nobutaka Fujisawa
Atsushi Nakajima
Publikationsdatum
01.06.2011
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 6/2011
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-011-0393-y

Weitere Artikel der Ausgabe 6/2011

Journal of Gastroenterology 6/2011 Zur Ausgabe

Original Article—Liver, Pancreas, and Biliary Tract

Pomalidomide suppresses cerulein-induced acute pancreatitis in mice

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.